Corporate
-
Regulatory Bodies & Rulings
Industry & Economy
-
Health
Ranbaxy gets approval for children's HIV drug
Our Bureau
New Delhi
,
Aug. 14
Ranbaxy Laboratories Ltd on Monday announced that the company has received approval to manufacture and market Triviro-LNS kid and Triviro-LNS kid DS, both triple ARV combinations for children, in India.
The company has also filed the product with WHO Geneva for pre-qualification. The products are indicated for treatment of HIV infection in children.
"We hope that with these new formulations, we will be able to make accessible a high quality and convenient treatment to a large number of HIV-positive children who are currently among the therapeutically most neglected," said Mr Malvinder Mohan Singh, CEO and Managing Director, Ranbaxy.
Currently, HIV/AIDS kills about 5-lakh children every year. Both the approved formulations are scored dispersible tablets.
The products are designed to deliver three ARV drugs together in recommended strengths and simplify the delivery of a more accurate treatment to children in resource poor settings.
More Stories on :
Regulatory Bodies & Rulings |
Health |
Pharmaceuticals |
Children & Parenting |
Ranbaxy Laboratories Ltd
Article
E-Mail
::
Comment
::
Syndication
::
Printer Friendly Page
|
